outperform price
show spine naysay
remark stori transform past
month went period spotti result due one-off
event consist execut stori thought result
anoth datapoint support consist execut thesi
debat whether initi guid tad
conserv believ organ print met buysid
expect thought spine segment come driven
pullthrough associ mazor robot encourag
provid confid mdt soft tissu robot play
line launch us guidanc
cvg rtg mitg rais thought cvg rais
noteworthi provid support segment
grow replac hw abat
diabet segment lower think lower
relat revenu deferr relat upgrad program
chang share loss assumpt us day
calibr sensor launch come within next month
think get back share gain mode aid put
piec togeth think sustain
organ grower medium term given reiter
outperform rate share pt tweak
number came slightli equat price-to-earnings
overal strong quarter across top line broadli
us diabet came us weak result
tariff fx weigh remain net hw
pleas see analyst certif import disclosur page report evercor isi affili seek busi
compani cover research report investor awar firm may conflict interest could affect object
report investor consid report singl factor make invest decis
organ revenue growth reiter acceler cours year north
fx reiter
oper margin expans reiter expans
ep rais prior
rtg rais prior
diabet lower lsd prior lower end
mitg rais prior
cvg rais prior
adjust tax lower prior
diabet flat slightli
highlight prepar remark
new product quarter
mida mr system us
eu launch later fy
evolut pro us late
inpact admir avf
cobalt chrome icd crt-d
percept db
ablat cathet eu
valiant navion thorac stent graft japan
attain stabil activ fixat crt patient lead japan
percepta crtp japan
declin lsd us
share loss ahead new product
product launch key us time growth
placement mazor signific ahead market pull help overal biz
data aha strong despit small data set
data set consist w/ fda want see led submiss
maintain expect market growth bn
trial aha good news tavr
incid pool vs preval pool make conserv market opportun
market come short term
medium term return msd-hsd
flat next quarter two
next-gen intelli reveal nan
current iter sale strong
micrastim recharg submit mid
interstiim recharg free around time
capit alloc granular level goe wamgr growth
focu innovation-driven growth
next fy replac net basi across ccrhf neutral growth
diabet growth still acceler w/ regardless new competit offer due differenti
diabet still small mix
new mfg process transient
open lot capabl miniatur improv diabet offer etc
spine market market improv slightli
neurosurgeri outperform market thank mazor market leadership
dcb outlook sequenti improv anniversari
dcb better expect cvg new product launch add confid
lvad posit stabil leadership chang place improv outlook
lr tavr share roughli equival offer share among lr patient pend futur data
cgm reduc calibr first-day
synergi take add form factor advantag
tariff remov could improv immedi full benefit
potenti upsid us tax rate
japan inflect acceler japan took place
algorithm collect data submit yet data present
defer revenu captur still uncertain need see year first
manag call open investor sell side
fx remain modest hw hedg gain offset
confid avf immin
valuat methodolog base mix discount cash flow analysi rel valuat multipl
risk valuat includ regulatori risk overal market risk well unforeseen event relat individu cover
compani broader sector includ new competit product technolog
articl articl
time dissemin novemb
analyst jon bristow vijay kumar primarili respons prepar research report attest follow view
opinion render research report reflect person view subject compani issuer part
research analyst compens directli relat specif recommend view research report
